Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents

摘要

Background:The increasing incidence of pediatric hospitalizations associated with coronavirus disease 2019(Covid-19)caused by the B.1.617.2(delta)variant of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)in the United States has offered an opportunity to assess the real-world effectiveness of the BNT162b2 messenger RNA vaccine in adolescents between 12 and 18 years of age.